Abstract | BACKGROUND: METHODS: A literature search up to December 2012 on the morbidity of RSV bronchiolitis in CF patients and on the safety and efficacy of palivizumab in those patients was performed. A random-effects meta-analysis was conducted for those studies meeting pre-specified search criteria. Historical controls were allowed. RESULTS: The number of patients who received palivizumab was 354 and the hospital admission rate was 0.018 (95% CI 0.0077-0.048). The corresponding number in the non-treated groups was 463 patients with an admission rate of 0.126 (95% CI 0.086-0.182) (Q=13.9; p<0.001). CONCLUSION:
Palivizumab may have a role in the prevention of severe lower airway infection by RSV in CF patients.
|
Authors | M Sánchez-Solis, S Gartner, V Bosch-Gimenez, L Garcia-Marcos |
Journal | Allergologia et immunopathologia
(Allergol Immunopathol (Madr))
2015 May-Jun
Vol. 43
Issue 3
Pg. 298-303
ISSN: 1578-1267 [Electronic] Singapore |
PMID | 24231153
(Publication Type: Journal Article, Meta-Analysis, Review)
|
Copyright | Copyright © 2013 SEICAP. Published by Elsevier Espana. All rights reserved. |
Chemical References |
- Antiviral Agents
- Palivizumab
|
Topics |
- Animals
- Antiviral Agents
(therapeutic use)
- Cystic Fibrosis
(complications, drug therapy)
- Hospitalization
- Humans
- Palivizumab
(therapeutic use)
- Randomized Controlled Trials as Topic
- Respiratory Syncytial Virus Infections
(etiology, prevention & control)
- Respiratory Syncytial Viruses
(immunology)
|